CD33 | Other immune checkpoint proteins | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲


Target id: 2601

Nomenclature: CD33

Abbreviated Name: SIGLEC-3

Family: Other immune checkpoint proteins, Sialic acid binding Ig like lectins, CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD33 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 364 19q13.3 CD33 CD33 molecule
Mouse - 403 7 B4 Cd33 CD33 antigen
Rat - - 1q22 Cd33 CD33 molecule
Previous and Unofficial Names
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
lintuzumab Hs Binding ~10.0 pKd 2
pKd ~10.0 (Kd ~1x10-10 M) [2]
vadastuximab talirine Hs Binding 9.3 pKd 5
pKd 9.3 (Kd 5x10-10 M) [5]
Description: Saturation binding in HEL 92.1.7 cells endogenously expressing human CD33.
gemtuzumab ozogamicin Hs Binding - - 1
Antibody Comments
Evidence of the effectiveness of gemtuzumab ozogamicin centers on the drug's ability to inhibit the growth of leukemic cells in vitro and in vivo [3,6-7].


Show »

1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]

2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52 (24): 6761-7. [PMID:1458463]

3. Frankel AE, Sievers EL, Scheinberg DA. (2000) Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother. Radiopharm., 15 (5): 459-76. [PMID:11155818]

4. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood, 105 (3): 1256-64. [PMID:15388576]

5. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP et al.. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood, 122 (8): 1455-63. [PMID:23770776]

6. McGavin JK, Spencer CM. (2001) Gemtuzumab ozogamicin. Drugs, 61 (9): 1317-22; discussion 1323-4. [PMID:11511025]

7. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97 (10): 3197-204. [PMID:11342449]

How to cite this page

Other immune checkpoint proteins: CD33. Last modified on 02/07/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY,